戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eated with trypsin or the protease inhibitor leupeptin.
2 regulation by lysosome-disrupting agents and leupeptin.
3  of falcipain-3 in complex with the aldehyde leupeptin.
4  A and tunicamycin, but not by wortmannin or leupeptin.
5 n but not by the active site-binding peptide leupeptin.
6 p. DU-145 tumor xenografts were treated with leupeptin.
7 ase in proteolytic activity was inhibited by leupeptin.
8 ) and was relatively insensitive to EDTA and leupeptin.
9  was not inhibited by the protease inhibitor leupeptin.
10 resence or absence of the protease inhibitor leupeptin (10 microM).
11 1 mm), phenylmethylsulfonyl fluoride (3 mm), leupeptin (100 microm), antipain (IC(50) = 2 microm), Hg
12  (0.2 microM) or with the protease inhibitor leupeptin (100 microM).
13 um iodide uptake, was partially prevented by leupeptin (5 mM) and completely prevented by antipain (2
14 ping sugar Neu5Ac as a selective elicitor of leupeptin, a protease inhibitor prevalent in clinical lu
15 c trypsin inhibitor (BPTI), benzamidine, and leupeptin affinities and activity and pH-rate profiles o
16 reover, these mutations decrease kcat/Km and leupeptin affinity in parallel with the decrease in stab
17 lpain inhibitor I, calpain inhibitor II, and leupeptin all provided significant protection of SGNs ag
18  MDL28,170, calpain inhibitors I and II, and leupeptin (all 1-100 microM) had little effect on the de
19                Treatment of PS-/- cells with leupeptin, an inhibitor of cysteine proteases, led to si
20                                              Leupeptin and a mixture of proteinase inhibitors also at
21 y mixed-type inhibition with the affinity of leupeptin and aprotinin to the factor XIa-factor IX comp
22                                 As expected, leupeptin and aprotinin were competitive with respect to
23  XIa heavy chain affects the interactions of leupeptin and aprotinin with the active site.
24 ssay, we found that the peptidic inhibitors, leupeptin and aprotinin, exhibited similar potencies in
25   Inhibitors of tryptase activity, including leupeptin and benzamidine hydrochloride, significantly d
26 s inhibited by subtilase-specific inhibitors leupeptin and chymostatin.
27  cells in ammonium chloride, concanamycin A, leupeptin and E-64.
28 rs, but not by lysosomal protease inhibitors leupeptin and E64.
29 eas prior exposure of P. gingivalis cells to leupeptin and especially acetyl-Leu-Val-Lys-aldehyde (wh
30                       Lysosomotrophic agents leupeptin and pepstatin A were ineffective in inhibiting
31 nd ALLN rather than the lysosomal inhibitors leupeptin and pepstatin A, suggesting that ubiquitinated
32 l inhibition of cathepsins was achieved with leupeptin and pepstatin A.
33 oteinases (aprotinin), cysteine proteinases (leupeptin) and urokinase (amiloride), altered mandibular
34 es have been discovered such as chymostatin, leupeptin, and fellutamide; however, the biosynthetic or
35 to the cysteine protease inhibitors E-64 and leupeptin, and over 50-fold more sensitive to the aspart
36  and serine protease inhibitors, i.e., E64d, leupeptin, and zinc chloride, inhibited viral RNA synthe
37             Recombinant PRCP is inhibited by leupeptin, angiotensin II, bradykinin, anti-PRCP, diisop
38 SF, aprotinin, pancreatic trypsin inhibitor, leupeptin, antipain, and EDTA could not prevent histatin
39 e prostasins resist antiproteases, including leupeptin, aprotinin, serpins, and alpha2-macroglobulin,
40 nhibited by the endocytic pathway inhibitors leupeptin, bafilomycin A1, and monensin.
41 system that was inhibited by E-64, EDTA, and leupeptin but not inhibitors of serine and aspartic prot
42   Pancreasin is inhibited by benzamidine and leupeptin but resists several classic inhibitors of tryp
43 protease inhibitors aprotinin, pepstatin, or leupeptin but was inhibited in a dose-dependent manner b
44  blocked by the cysteine protease inhibitor, leupeptin, but not by proteasome inhibitors, which is op
45         Cathepsin K is inhibited by E-64 and leupeptin, but not for by pepstatin, EDTA, phenylmethyls
46        Incubation with either chloroquine or leupeptin, but not lactacystin, led to intracellular sta
47 owever, the addition of protease inhibitors, leupeptin, calpain inhibitor I, E-64, or pepstatin (0.5
48 al production and proteolytic degradation of leupeptins can be associated with animal colonization ph
49 at certain protease inhibitors, particularly leupeptin, can block, by up to 95%, the anti-HIV activit
50  parasites carrying this mutation survived a leupeptin challenge significantly better than a transfec
51 , pyrroloindole alkaloids, angucyclines, and leupeptins chemical families.
52 the preferential-but-less-specific inhibitor leupeptin decreased transmigration of both cell lines ac
53                        In Ringer's solution, leupeptin delayed globulization without significantly af
54                                 z-VAD-FMK or leupeptin delayed, but did not inhibit, cell detachment
55 in clinical lung isolates of K. oxytoca, and leupeptin-derived pyrazinone biosynthesis.
56 king constitutive lysosomal degradation with leupeptin did not induce significant changes in KCC2 pro
57 differential sensitivity of Ag processing to leupeptin, different duration required for epitope gener
58  protease inhibitors that includes bestatin, leupeptin, E64, AEBSF, and aprotinin.
59 inhibitors, including antipain, chymostatin, leupeptin, elastatinal, and microbial alkaline protease
60 frontal and entorhinal cortex suggested that leupeptin exacerbated Abeta40 toxicity.
61                               Chloroquine or leupeptin had no effect on the apical to basolateral tra
62                                              Leupeptin has been characterized as a slow binding inhib
63                    We identified a family of leupeptins in gammaproteobacterial pathogens, including
64 covery that the calpain inhibitors MG101 and leupeptin inactivate globupain activity with IC(50) valu
65 f 0.5 mM of the protease inhibitors E-64 and leupeptin increased the globulization time to 60 and 100
66 ibitors, the "defined trypsin inhibitor" and leupeptin, increased CD138 expression on TCRB+CD138- cel
67    Inhibition of the proteolytic activity by leupeptin increases T:(g) without affecting the gain in
68 132 or lactacystin or high concentrations of leupeptin, indicating involvement of ubiquitin-proteasom
69                   Intriguingly, Abeta40 plus leupeptin induced intracellular accumulation of the more
70                                              Leupeptin-induced autophagic impairment increased the nu
71 letely degraded and complexes containing the leupeptin-induced fragment of Ii (LIP) and class II mole
72 ss II-associated invariant chain peptide and leupeptin-induced protein in the 43(HIV) cells.
73                                              Leupeptin infusion previously has been reported to inter
74 l and lactacystin but not lysosome inhibitor leupeptin inhibited the degradation of Y611H mutant chan
75 lization of the ligand, both chloroquine and leupeptin inhibited the intracellular degradation of 125
76                                     A single leupeptin injection resulted in a rapid massive accumula
77 ensitive to the lysosomal protease inhibitor leupeptin, insensitive to proteasome inhibition, and att
78                                              Leupeptin is a bacterial small molecule that is used wor
79 ed by the cysteine protease inhibitors E-64, leupeptin, Mu-Np2-HphVS-2Np, Mu-Leu-HpHVSPh and the cath
80 itors Ni2+ and Zn2+, and protease inhibitor, leupeptin, Na+-free and K+-free media and Ca2+-containin
81 and fibripositors and there was no effect of leupeptin on fibricarrier or fibripositor number and siz
82         This effect is partially reversed by leupeptin or MG132, indicating that both the lysosomal a
83 ctivity by using a serine protease inhibitor leupeptin or two structurally different protease-activat
84  cysteine proteases (E64), serine proteases (leupeptin), or metalloproteases (1, 10-phenanthroline) h
85 xysuccinyl-l-leucylamido-4-guanidino butane, leupeptin, pepstatin-A, chloroquine, and NH(4)Cl did not
86 ntrast, inhibitors of lysosomal degradation (leupeptin/pepstatin) and endocytosis (chloroquine) had l
87                                              Leupeptin plus Abeta40 caused limited but significant ne
88 hosphatidyl inositol 3-kinase inhibitor, and leupeptin plus E64 (inhibitors of lysosomal proteases).
89 showing that the cysteine protease inhibitor leupeptin prevented Sp1 degradation.
90 stration of the cysteine protease inhibitor, leupeptin, promoted accumulation of autophagic vacuoles
91  by another mechanism, in a chymotrypsin- or leupeptin protease-inhibitable manner.
92              Pretreatment of CD8+ cells with leupeptin reduces CNAR, further supporting an inhibitory
93 s directly to both altered PSAC activity and leupeptin resistance.
94        A single CLAG3 mutation (A1210T) in a leupeptin-resistant PSAC mutant falls within this transm
95                               Treatment with leupeptin restored flurazepam lowered receptor surface l
96 Abeta40 with the cysteine protease inhibitor leupeptin resulted in increased extracellular and intrac
97 ization studies performed in the presence of leupeptin revealed that WNK4 enhanced the accumulation o
98               Cleavage measured in vitro was leupeptin sensitive and dependent on calcium.
99 was delivered to lysosomes and degraded by a leupeptin-sensitive pathway.
100 was endocytosed and subsequently degraded by leupeptin-sensitive proteases.
101  constitutive endocytosis and degradation by leupeptin-sensitive proteases.
102             The lysosomal protease inhibitor leupeptin slowed ferritin turnover and also retarded MC
103 ed after culture with the protease inhibitor leupeptin, suggesting that one or more endoproteases oth
104 heat inactivation and the protease inhibitor leupeptin, suggesting that the proteolytic activity of t
105 d 0.5 mM of the cysteine protease inhibitor, leupeptin, T:(g) increased to 100 minutes, without affec
106  Using z-VAD-FMK to inhibit Kgp activity and leupeptin to inhibit Rgp activity in gingipain-active W8
107          Such complexes are only observed in leupeptin-treated cells in which Ii fails to be complete
108 r invasion into the diaphragm was reduced by leupeptin treatment for both the PA and wild-type DU-145
109 as monitored as a function of time after the leupeptin treatment with quantitative ultrastructural an
110              Over a 12-week period after the leupeptin treatment, the amounts of inclusion material a
111 al, but not the lysosomal protease inhibitor leupeptin, were found to effectively inhibit the proteol
112                        Furthermore, E64D and leupeptin, which are able to function as inhibitors of a
113 vitreal injections of the protease inhibitor leupeptin, which induces a rapid accumulation of lipofus
114                      Treatment of cells with leupeptin, which inhibits invariant chain degradation, l

 
Page Top